CT perfusion and MRI: A combined approach for hepatocellular carcinoma diagnosis and follow-up after locoregional treatment

被引:0
|
作者
Kalarakis, Georgios [1 ,2 ,3 ]
Chryssou, Evangelia G. [4 ]
Perisinakis, Kostas [8 ]
Klontzas, Michail E. [2 ,3 ,4 ]
Samonakis, Dimitrios [5 ]
Hatzidakis, Adam [6 ,7 ]
机构
[1] Karolinska Univ Hosp, Dept Neuroradiol, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Radiol, Stockholm, Sweden
[3] UNIV CRETE, Sch Med, Dept Radiol, Iraklion, Greece
[4] Univ Hosp Heraklion, Dept Med Imaging, Iraklion, Greece
[5] Univ Hosp Heraklion, Dept Gastroenterol & Hepatol, Iraklion, Greece
[6] AHEPA Univ Hosp, Dept Radiol, Thessaloniki, Greece
[7] Aristotle Univ Thessaloniki, Sch Med, Thessaloniki, Greece
[8] Univ Crete, Sch Med, Dept Med Phys, Div Radiol, Iraklion, Greece
关键词
Hepatocellular carcinoma; Perfusion imaging; Magnetic Resonance Imaging; Transarterial chemoembolization; Microwave ablation; LI-RADS; COMPUTED-TOMOGRAPHY; TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; LIVER; MULTIPHASE; CANCER;
D O I
10.1016/j.ejrad.2025.111928
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: CT liver perfusion (CTLP) has been well validated for hepatocellular carcinoma (HCC) detection, characterization, and treatment response evaluation. However, its role in HCC management algorithms remains unclear. This study aims to assess the diagnostic performance of CTLP alone or as an adjunct to MRI in patients considered for- or undergoing locoregional treatment for HCC. Material and Methods: Thirty-nine patients under HCC surveillance (36 male, 31 cirrhotic, 16 pretreatment, 19 post-transarterial chemoembolization, 2 post-ablation) underwent MRI and CTLP in a single center within a 45- day interval. Two readers identified and characterized all observations on MRI using Liver Imaging Reporting and Data System (LI-RADS) v2018 criteria. CTLP assessment was based on Mean Slope of Increase (MSI), Time To Peak (TTP), Hepatic arterial Blood Flow (HaBF) and Hepatic Arterial Fraction (HAF) maps and established cutoffs. Diagnostic performance of MRI, CTLP, and their combination was evaluated for treated and untreated lesions using imaging or pathology as reference standard. Results: Of the total 33 treated and 61 untreated lesions, 13 and 41 were considered viable HCCs. CTLP demonstrated 75.9 % sensitivity and 95 % specificity compared to 72.2 % and 100 % for MRI (p > 0.05). Combining both modalities increased sensitivity to 85.2 % (p < 0.05) and maintained specificity at 97.5 % (p > 0.05). The combined approach led to an LR category change in 5 treated and 19 untreated lesions and affected management in 5 cases. Conclusion: CTLP and MRI have comparable diagnostic performance for HCC. A combined approach improves sensitivity, without sacrificing specificity. This approach might enable more efficient patient selection for early and individualized loco-regional treatment.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma
    Rodolfo Sacco
    Lorenzo Faggioni
    Irene Bargellini
    Antonio Romano
    Marco Bertini
    Barbara Ginanni
    Valentina Battaglia
    Michele Bertoni
    Elena Bozzi
    Graziana Federici
    Salvatore Metrangolo
    Giuseppe Parisi
    Emanuele Neri
    Elisabetta Sodini
    Emanuele Tumino
    Giampaolo Bresci
    Carlo Bartolozzi
    Journal of Gastrointestinal Cancer, 2012, 43 (Suppl 1) : 234 - 238
  • [2] Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment
    Trojan, J
    Raedle, J
    Zeuzem, S
    DIGESTION, 1998, 59 : 72 - 74
  • [3] Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up
    Guan, Yong-Song
    Sun, Long
    Zhou, Xiang-Ping
    Li, Xiao
    Zheng, Xiao-Hua
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (24) : 3543 - 3548
  • [4] Hepatocellular carcinoma treated with interventional procedures:CT and MRI follow-up
    Yong-Song Guan Long Son Xiang-Ping Zhou Xiao Li Xiao-Hua Zheng Department of Radiology
    World Journal of Gastroenterology, 2004, (24) : 3543 - 3548
  • [5] Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up
    Kaufmann, Sascha
    Thaiss, Wolfgang M.
    Schulze, Maximilian
    Bitzer, Michael
    Lauer, Ulrich
    Nikolaou, Konstantin
    Horger, Marius
    ACTA RADIOLOGICA, 2018, 59 (07) : 765 - 772
  • [6] Hepatocellular carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Parikh, P.
    Malhotra, H.
    Jelic, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 27 - 28
  • [7] Hepatocellular carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Jelic, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 41 - 45
  • [8] Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Jelic, S.
    Sotiropoulos, G. C.
    ANNALS OF ONCOLOGY, 2010, 21 : v59 - v64
  • [9] Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Vogel, A.
    Cervantes, A.
    Chau, I.
    Daniele, B.
    Llovet, J.
    Meyer, T.
    Nault, J. -C.
    Neumann, U.
    Ricke, J.
    Sangro, B.
    Schirmacher, P.
    Verslype, C.
    Zech, C. J.
    Arnold, D.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 238 - 255
  • [10] Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma
    Arora, Anil
    Kumar, Ashish
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2014, 4 : S126 - S129